EGFR and neoplasm: Cetuximab is a recombinant human/mouse chimeric EGFR antagonist mAb of IgG1 isotype that binds to the extracellular ligand-binding domain of the EGFR, blocks the binding of EGF and other ligands to the EGFR and the ligand-induced phosphorylation and activation of EGFR and downstream cell signalling molecules, ultimately leading to tumour growth inhibition and apoptosis [80].